Breaking News
Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations. To learn more, please visit www.pfizer.com.
Complete the 4-Dose Series of PREVENAR® at the 12-Month Visit* - *The 4th dose of Prevnar® is recommended at 12 to 15 months of age. - This Site is Intended for U.S. Health Care Professionals Only. - Please scroll down to see Important Safety Information. Important Safety Information

Adobe Flash Player Required; Certain portions of the PREVNAR website require the latest version of the free Adobe Flash Player. Click on the button to the right to download the latest player. Get Adobe Flash Player

Prevnar® Dosing Schedule

Approved For Routine Immunization Against Invasive Pneumococcal Disease in Infants and Toddlers1

Vaccine schedule for infants and toddlers1

Dose 1†

Dose 2†

Dose 3†

Dose 4†

2 Months

4 Months

6 Months

12-15 Months

May be given as early as 6 weeks
of age.

 

Should be administered at least 2 months after third dose, and not before 12 months of age.
  • †Dosing interval is 4-8 weeks

Back to Top

Administration for Previously Unvaccinated Older Infants and Children1

Vaccine schedule for previously
unvaccinated children 7 months of age1

Age at First Dose

Total Number of Doses

Dosing Information

7-11 months

3 doses

2 doses at least 4 weeks apart; third dose after 12 months of age and at least 2 months after the second dose

12-23 months

2 doses

2 doses at least 2 months apart

24 months
through 9 years

1 dose

1 dose

Please click here to view Prescribing Information for complete dosing schedule.

Rationale for immunization

  • Children through 59 months of age remain at risk for invasive pneumococcal disease10
  • Recent child care attendance may place children at greater risk for invasive pneumococcal disease16
  • Antibiotic resistance is a growing concern17
  • Minor illnesses, such as a mild upper respiratory infection with or without low-grade fever, are not generally contraindications to the administration of Prevnar®1

Back to Top

Important Safety Information

In clinical trials (n=18,168), the most frequently reported adverse events included injection site reactions, fever (38ºC/100.4ºF), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash.

Risks are associated with all vaccines, including Prevnar®. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. Prevnar® does not provide 100% protection against vaccine serotypes or protect against nonvaccine serotypes.

Please see Prescribing Information.

Indication

Prevnar® is indicated for active immunization of infants and toddlers against invasive disease caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F). The routine schedule is 2, 4, 6, and 12 to 15 months of age.

The decision to administer Prevnar® should be based primarily on its efficacy in preventing invasive pneumococcal disease. As with any vaccine, Prevnar® may not protect all individuals receiving the vaccine from invasive pneumococcal disease.

Prevnar® is also indicated for active immunization of infants and toddlers against otitis media caused by serotypes included in the vaccine. However, for vaccine serotypes, protection against otitis media is expected to be substantially lower than protection against invasive disease. Additionally, because otitis media is caused by many organisms other than serotypes of S. pneumoniae represented in the vaccine, protection against all causes of otitis media is expected to be low.

This vaccine is not intended to be used for treatment of active infection.